清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Once-Daily Plazomicin for Complicated Urinary Tract Infections

医学 美罗培南 泌尿系统 氨基糖苷 内科学 置信区间 抗生素 外科 抗生素耐药性 微生物学 生物
作者
Florian Wagenlehner,Daniel J. Cloutier,Allison Komirenko,Deborah Cebrik,Kevin M. Krause,Tiffany R. Keepers,Lynn E. Connolly,Loren Gregory Miller,Ian R. Friedland,Jamie P. Dwyer
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:380 (8): 729-740 被引量:223
标识
DOI:10.1056/nejmoa1801467
摘要

BACKGROUND: The increasing multidrug resistance among gram-negative uropathogens necessitates new treatments for serious infections. Plazomicin is an aminoglycoside with bactericidal activity against multidrug-resistant (including carbapenem-resistant) Enterobacteriaceae. METHODS: We randomly assigned 609 patients with complicated urinary tract infections (UTIs), including acute pyelonephritis, in a 1:1 ratio to receive intravenous plazomicin (15 mg per kilogram of body weight once daily) or meropenem (1 g every 8 hours), with optional oral step-down therapy after at least 4 days of intravenous therapy, for a total of 7 to 10 days of therapy. The primary objective was to show the noninferiority of plazomicin to meropenem in the treatment of complicated UTIs, including acute pyelonephritis, with a noninferiority margin of 15 percentage points. The primary end points were composite cure (clinical cure and microbiologic eradication) at day 5 and at the test-of-cure visit (15 to 19 days after initiation of therapy) in the microbiologic modified intention-to-treat population. RESULTS: Plazomicin was noninferior to meropenem with respect to the primary efficacy end points. At day 5, composite cure was observed in 88.0% of the patients (168 of 191 patients) in the plazomicin group and in 91.4% (180 of 197 patients) in the meropenem group (difference, -3.4 percentage points; 95% confidence interval [CI], -10.0 to 3.1). At the test-of-cure visit, composite cure was observed in 81.7% (156 of 191 patients) and 70.1% (138 of 197 patients), respectively (difference, 11.6 percentage points; 95% CI, 2.7 to 20.3). At the test-of-cure visit, a higher percentage of patients in the plazomicin group than in the meropenem group were found to have microbiologic eradication, including eradication of Enterobacteriaceae that were not susceptible to aminoglycosides (78.8% vs. 68.6%) and Enterobacteriaceae that produce extended-spectrum β-lactamases (82.4% vs. 75.0%). At late follow-up (24 to 32 days after initiation of therapy), fewer patients in the plazomicin group than in the meropenem group had microbiologic recurrence (3.7% vs. 8.1%) or clinical relapse (1.6% vs. 7.1%). Increases in serum creatinine levels of 0.5 mg or more per deciliter (≥40 μmol per liter) above baseline occurred in 7.0% of patients in the plazomicin group and in 4.0% in the meropenem group. CONCLUSIONS: Once-daily plazomicin was noninferior to meropenem for the treatment of complicated UTIs and acute pyelonephritis caused by Enterobacteriaceae, including multidrug-resistant strains. (Funded by Achaogen and the Biomedical Advanced Research and Development Authority; EPIC ClinicalTrials.gov number, NCT02486627.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Tracy发布了新的文献求助10
2秒前
meeteryu完成签到,获得积分10
19秒前
清爽的孤丝完成签到,获得积分10
27秒前
NexusExplorer的应助被王磊磊0811采纳,获得10
29秒前
快乐的雁露完成签到,获得积分10
36秒前
打打的应助被科研通管家采纳,获得10
40秒前
40秒前
研友_VZG7GZ的应助被科研通管家采纳,获得10
40秒前
犹豫静白完成签到,获得积分10
50秒前
超级的迎梅完成签到,获得积分10
55秒前
Sunny完成签到,获得积分10
56秒前
儒雅的半青完成签到,获得积分10
58秒前
1分钟前
1分钟前
光亮的成败完成签到,获得积分10
1分钟前
烂漫的诗蕊完成签到,获得积分10
1分钟前
笨笨的夏柳完成签到,获得积分10
1分钟前
平常觅风完成签到,获得积分10
1分钟前
76完成签到 ,获得积分10
1分钟前
苹果元瑶完成签到 ,获得积分10
2分钟前
能干的颦完成签到,获得积分10
2分钟前
Khan完成签到,获得积分10
2分钟前
含蓄的新柔完成签到,获得积分10
2分钟前
无心的柚子完成签到,获得积分10
2分钟前
瘦瘦的巧凡完成签到,获得积分10
2分钟前
如意嫣完成签到,获得积分10
2分钟前
Aman完成签到,获得积分10
3分钟前
wenbinvan完成签到,获得积分0
3分钟前
思源的应助被Tracy采纳,获得10
3分钟前
房天川完成签到 ,获得积分10
3分钟前
外向的念之完成签到,获得积分10
3分钟前
笑点低小霜完成签到,获得积分10
3分钟前
刻苦的刚完成签到,获得积分10
3分钟前
3分钟前
重要盼易完成签到,获得积分10
3分钟前
Tracy发布了新的文献求助10
3分钟前
典雅的醉易完成签到,获得积分10
3分钟前
冷酷紫烟完成签到,获得积分10
3分钟前
深情的晓槐完成签到,获得积分10
4分钟前
Aman完成签到,获得积分10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158937
求助须知:如何正确求助?哪些是违规求助? 9554526
关于积分的说明 21719385
捐赠科研通 7748487
什么是DOI,文献DOI怎么找? 3427107
关于科研通互助平台的介绍 2552013
邀请新用户注册赠送积分活动 2471370